The EEA1 Knockout 786-O Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population, in which the EEA1 gene encoding early endosome antigen 1 has been disrupted. This pooled knockout product derives from the 786-O cell line and is supplied as a heterogeneous mixture of edited cells, making it suitable for studying loss-of-function effects without clonal selection biases. The polyclonal format preserves genetic diversity while achieving robust target gene disruption, enabling researchers to investigate the collective consequences of EEA1 ablation on endosomal trafficking and related cellular processes.
The 786-O cell line is a widely used human renal cell adenocarcinoma line of kidney epithelial origin, serving as a standard in vitro model for clear cell renal cell carcinoma (ccRCC). These adherent epithelial cells are characterized by constitutive activation of hypoxia-inducible factor pathways due to VHL tumor suppressor gene loss, which mimics the molecular pathology of most sporadic ccRCC cases. The 786-O line provides a physiologically relevant host context for examining how endosomal dysregulation influences cancer cell signaling, growth, and drug response.
EEA1 is a peripheral membrane protein that functions as a key tethering factor in early endosome fusion. It binds simultaneously to the GTP-bound form of Rab5 and to PI3P on endosomal membranes, bridging apposing ends to facilitate homotypic fusion and maturation. Acting downstream of Rab5??which is activated by the Rabex-5/Rabaptin-5 complex??EEA1 also interacts with Syntaxin-13 and SNAREs to coordinate docking. This activity is essential for endocytic trafficking, receptor recycling, and termination of signaling from internalized receptors. Loss of EEA1 thus disrupts these processes, impairing receptor tyrosine kinase recycling, autophagy initiation via PI3K, and lysosomal delivery.
In the 786-O renal cell carcinoma model, EEA1 disruption allows interrogation of how endosomal sorting errors influence oncogenic signaling. Renal cancer cells often display dysregulated trafficking, altering surface expression of growth factor receptors and integrins. Knocking out EEA1 helps dissect the role of early endosome dynamics in PI3K/AKT and other hyperactivated cascades in ccRCC. This model further enables evaluation of how endosomal dysfunction affects drug internalization and intracellular distribution, informing resistance mechanisms and strategies to enhance targeted therapy in kidney cancer.
The EEA1 Knockout 786-O Polyclonal Cells are suited for applications including immunofluorescence and confocal microscopy to monitor endosomal morphology changes, transferrin uptake assays to assess receptor internalization kinetics, and co-immunoprecipitation to study interactions of EEA1-effectors such as Rab5 and Rabaptin-5. They also support autophagy flux measurements and signal transduction studies where endosomal sorting is pivotal. For detailed specifications or experimental consultation, please reach out to Ascent Research.
